- Home
- CCEC vs CMPS Comparison
CCEC vs CMPS Comparison
Compare CCEC & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCEC | CMPS |
|---|---|---|
| Founded | 2007 | 2020 |
| Country | Greece | United Kingdom |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CCEC | CMPS |
|---|---|---|
| Price | $20.22 | $12.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $23.67 | ★ $25.38 |
| AVG Volume (30 Days) | 13.7K | ★ 3.5M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.75% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $19.82 | N/A |
| Revenue Next Year | $39.95 | N/A |
| P/E Ratio | $4.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.77 | $2.25 |
| 52 Week High | $24.83 | $14.76 |
Technical Indicators
Market Signals| Indicator | CCEC | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 39.00 | 58.33 |
| Support Level | $20.05 | $5.48 |
| Resistance Level | $21.79 | $14.76 |
| Average True Range (ATR) | 0.93 | 0.98 |
| MACD | -0.28 | -0.16 |
| Stochastic Oscillator | 2.12 | 43.26 |
Price Performance
Historical ComparisonAbout CCEC Capital Clean Energy Carriers Corp.
Capital Clean Energy Carriers Corp is an international shipping company. It is the platform of gas carriage solutions with a focus on the energy transition. The company owns 20 high-specification vessels, including 12 latest-generation LNG carriers (LNG/Cs) and eight legacy Neo-Panamax container vessels.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.